Freshfields advises on listing of Giant Biogene Holding Co., Ltd on HKSE

Freshfields Bruckhaus Deringer (‘Freshfields’) has provided Hong Kong and US law advice to Goldman Sachs (Asia) L.L.C. and China International Capital Corporation Hong Kong Securities Limited, the joint sponsors and the underwriters in the global offering and listing of shares of Giant Biogene Holding Co., Ltd on the Hong Kong Stock Exchange (‘HKSE’). The transaction raised proceeds of approximately HK$549.4m (US$70m) before any exercise of the Over-allotment Option. Trading in the shares commenced today (4 November 2022).

Giant Biogene Holding Co., Ltd is a leader in the bioactive ingredient-based professional skin treatment product industry in China. The company designs, develops and manufactures professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenosides technology-based functional foods. The company utilises proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturising and immunity improvement with a broad range of applications in the beauty and health sectors.

The Freshfields team advising on the transaction was led by partner and head of China ECM Richard Wang, partner Howie Farn and counsel Chris Fu. They were supported by senior associate Quan Zhou, associates Xinyu Wang, Yuwei Tian, Jianhua Feng and Zhuolin Li.